News | June 08, 2024
Briefs: Dr. Reddy's Laboratories and Ami Organics
Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility
Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Shelter Pharma Limited secured an order from Berlin International Medical Co D3Cure 50 ml x 30000 pcs
This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process
Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Subscribe To Our Newsletter & Stay Updated
